Effect of Symptom Management on Inflammation and Survival in Metastatic Lung Cancer

Completed

Conditions studied: Lung Neoplasms, Carcinoma, Non-Small-Cell Lung

In brief

There is a growing body of evidence that implicates inflammation as a mechanism of disease progression and reduced survival in patients with advanced cancer. Elevated c-reactive protein levels have been shown to be associated with reduced performance status, specific cancer related symptoms and reduced overall survival. C-reactive protein levels are a surrogate for IL-6 expression. IL-6 is part of an inflammatory signature predicting cancer recurrence. VeriStrat® is a multivariate test which measures protein expression related to a host/tumor interaction mediated by inflammation. The investigators hope to examine the relationship between quality of life outcomes per FACT-L survey and correlate them with changes in c-reactive protein levels and the VeriStrat® status. The hypothesis of this study is that the remarkable survival benefit in the Temel study is mediated by reduced inflammation with improvement of symptom control.

Key facts

Study ID

NCT02271581

Run by

Leo W. Jenkins Cancer Center

People needed

38

Starts

2014-10-01

Expected to finish

2019-04-19

Last updated by the study team

2020-11-04

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Confirmed diagnosis of stage IV non-small cell lung cancer
• Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2
• Able to read and respond to questions in English

You may not qualify if…

• Small Cell Lung Cancer

Where it is running

• Leo Jenkins Cancer Center — Greenville, North Carolina, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.